- Home
- NRIX vs HTFL Comparison
NRIX vs HTFL Comparison
Compare NRIX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | HTFL |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NRIX | HTFL |
|---|---|---|
| Price | $25.37 | $56.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $34.50 | ★ $47.22 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 10-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ 3.26 | N/A |
| Revenue | $76,987,000.00 | ★ $176,034,000.00 |
| Revenue This Year | $786.93 | $41.33 |
| Revenue Next Year | N/A | $24.23 |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | ★ 99.31 | 39.92 |
| 52 Week Low | $11.19 | $20.13 |
| 52 Week High | $28.23 | $57.25 |
Technical Indicators
Market Signals| Indicator | NRIX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 66.26 |
| Support Level | $24.61 | $46.46 |
| Resistance Level | $28.23 | N/A |
| Average True Range (ATR) | 1.21 | 3.08 |
| MACD | 0.39 | 0.52 |
| Stochastic Oscillator | 81.41 | 90.44 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.